HK1223355A1 - 作為 配體的苯並咪唑衍生物 - Google Patents

作為 配體的苯並咪唑衍生物

Info

Publication number
HK1223355A1
HK1223355A1 HK16111531.5A HK16111531A HK1223355A1 HK 1223355 A1 HK1223355 A1 HK 1223355A1 HK 16111531 A HK16111531 A HK 16111531A HK 1223355 A1 HK1223355 A1 HK 1223355A1
Authority
HK
Hong Kong
Prior art keywords
ligands
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
HK16111531.5A
Other languages
English (en)
Inventor
Olaf Peters
Nico Bruer
Ulrich Bothe
Marcus Koppitz
Jens Nagel
Gernot Langer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1223355A1 publication Critical patent/HK1223355A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16111531.5A 2013-12-19 2016-10-04 作為 配體的苯並咪唑衍生物 HK1223355A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198448 2013-12-19
PCT/EP2014/077955 WO2015091475A1 (de) 2013-12-19 2014-12-16 Benzimidazolderivate als ep4-liganden

Publications (1)

Publication Number Publication Date
HK1223355A1 true HK1223355A1 (zh) 2017-07-28

Family

ID=49876417

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111531.5A HK1223355A1 (zh) 2013-12-19 2016-10-04 作為 配體的苯並咪唑衍生物

Country Status (11)

Country Link
US (1) US10730856B2 (zh)
EP (1) EP3083603B1 (zh)
JP (1) JP6411513B2 (zh)
CN (1) CN105814038B (zh)
AR (1) AR098843A1 (zh)
CA (1) CA2934094C (zh)
ES (1) ES2651857T3 (zh)
HK (1) HK1223355A1 (zh)
TW (1) TW201607943A (zh)
UY (1) UY35906A (zh)
WO (1) WO2015091475A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018162562A1 (en) * 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド Ｎ－置換インドール誘導体
CA3060394A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
UA125123C2 (uk) 2017-05-18 2022-01-12 Ідорсія Фармасьютікалз Лтд Фенільні похідні як модулятори pge2 рецепторів
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
CN114249660B (zh) * 2021-12-10 2024-04-09 浙江工业大学 一种利用含醚键醇类衍生物的n-烷基化反应制备含醚芳胺衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE60113809T2 (de) 2000-01-18 2006-06-22 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
NZ535748A (en) 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
CN1671672A (zh) * 2002-07-31 2005-09-21 欧洲凯尔特股份有限公司 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途
US6949564B2 (en) 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
AU2004207675B2 (en) 2003-01-29 2010-05-20 Asterand Uk Acquisition Limited EP4 receptor antagonists
RS20060143A (en) 2003-09-03 2008-06-05 Pfizer Inc., Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
WO2005102389A2 (en) 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
BRPI0510598A (pt) 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
WO2009020588A1 (en) 2007-08-09 2009-02-12 Merck & Co., Inc. Process for making thiophene carboxamide derivative
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
US20110059962A1 (en) 2009-04-22 2011-03-10 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
JP6152643B2 (ja) * 2010-02-22 2017-06-28 株式会社ＡｓｋＡｔ Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
CA2934094A1 (en) 2015-06-25
UY35906A (es) 2015-07-31
JP2017500327A (ja) 2017-01-05
AR098843A1 (es) 2016-06-15
US20160318905A1 (en) 2016-11-03
EP3083603A1 (de) 2016-10-26
EP3083603B1 (de) 2017-09-13
JP6411513B2 (ja) 2018-10-24
CA2934094C (en) 2022-07-26
CN105814038A (zh) 2016-07-27
CN105814038B (zh) 2018-12-04
ES2651857T3 (es) 2018-01-30
TW201607943A (zh) 2016-03-01
WO2015091475A1 (de) 2015-06-25
US10730856B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
HK1220692A1 (zh) 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物
HK1215795A1 (zh) 鵝膏毒素衍生物
HK1223355A1 (zh) 作為 配體的苯並咪唑衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1223090A1 (zh) -氮雜吲哚衍生物
EP2906040A4 (en) NEW BENZIMIDAZOLE DERRAHYDROPYRANE DERIVATIVES
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
SG11201605189YA (en) Imidazopyrazinone derivatives
HK1213566A1 (zh) 新的四唑酮衍生物
HK1223621A1 (zh) 咪唑衍生物
HK1213885A1 (zh) 作為 抑制劑的咪唑並-三嗪衍生物
EP2968324A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives